EMEA Accepts Targanta's Oritavancin MAA for Review
Posted on: Thursday, 26 June 2008, 12:03 CDT
Targanta Therapeutics has announced that the European Medicines Agency has accepted for review its marketing authorization application for oritavancin, the company's novel semi-synthetic lipoglycopeptide antibiotic candidate with potent bactericidal activity against a broad spectrum of gram-positive bacteria.
Targanta is seeking approval of intravenous oritavancin in the EU for the treatment of complicated skin and soft tissue infections (cSSTI) caused by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
The oritavancin marketing authorization application (MAA)includes data from 19 clinical trials, including two pivotal Phase III clinical trials examining the safety and efficacy of intravenous oritavancin in the treatment of cSSTI both of which met their primary endpoints.
Mark Leuchtenberger, president and CEO of Targanta, said: "If regulatory discussions progress as anticipated and approval is received, we expect to launch oritavancin in the US in the first half of 2009. Given the standard regulatory review times in the EU, we hope to receive approval for oritavancin in late 2009."
Source: Datamonitor
Related Articles
- Targanta Therapeutics Announces Positive Top-Line Results From Oritavancin Phase 2 SIMPLIFI Trial
- Targanta's Oritavancin MAA Accepted for Review By EMEA
- Targanta Submits Marketing Authorization Application for Oritavancin
- Targanta Completes Enrollment in Phase 2 Oritavancin Infrequent Dosing Study
- Targanta Announces Launch of Oral Oritavancin Development Program Against C. Difficile Bacterial Infection
- FDA Accepts Targanta's Oritavancin NDA
- Targanta Announces FDA Acceptance of Oritavancin New Drug Application
- Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study
- Targanta Therapeutics: IPO Based on Oritavancin
- InterMune Announces Divestiture of Oritavancin
User Comments (0)
RSS Feeds